市場調査レポート
商品コード
1356794
抗結核治療薬市場レポート:2030年までの動向、予測、競合分析Anti-Tuberculosis Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
抗結核治療薬市場レポート:2030年までの動向、予測、競合分析 |
出版日: 2023年09月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
|
抗結核治療薬の動向と予測
世界の抗結核治療薬市場は、2024年から2030年までのCAGRが7.1%で、2030年までに推定21億米ドルに達すると予想されます。この市場の主な促進要因は、結核有病率の増加、結核啓発に対する政府組織のイニシアチブの高まり、新興諸国におけるMDRおよびXDR症例の急増です。世界の抗結核治療薬市場の将来性は、病院、専門クリニック、在宅医療市場における機会によって有望視されています。
抗結核治療薬市場の洞察
Lucintelの予測では、結核患者の増加と結核治療へのイソニアジドの採用増加により、イソニアジドが予測期間中に最も高い成長を遂げる見込みです。
この市場において、病院が最大のセグメントであり続けると思われます。
アジア太平洋は、政府イニシアチブの拡大、ジェネリックメーカーの増加、同地域におけるヘルスケアインフラの継続的な開発により、予測期間中に最も高い成長が見込まれます。
Anti-Tuberculosis Therapeutics Trends and Forecast
The future of the global anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030 with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.
A more than 150-page report is developed to help in your business decisions.
Anti-Tuberculosis Therapeutics by Segment
The study includes a forecast for the global anti-tuberculosis therapeutics by type, drug classes, end use, and region.
Anti-Tuberculosis Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:
Anti-Tuberculosis Therapeutics Market by Drug Classes [Shipment Analysis by Value from 2018 to 2030]:
Anti-Tuberculosis Therapeutics Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
Anti-Tuberculosis Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:
List of Anti-Tuberculosis Therapeutics Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies anti-tuberculosis therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the anti-tuberculosis therapeutics companies profiled in this report include-
Anti-Tuberculosis Therapeutics Market Insights
Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.
Within this market, hospitals will remain the largest segment due to .
APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.
Features of the Global Anti-Tuberculosis Therapeutics Market
Market Size Estimates: Anti-tuberculosis therapeutics market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Anti-tuberculosis therapeutics market size by type, drug classes, end use, and region. in terms of value ($B).
Regional Analysis: Anti-tuberculosis therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, drug classes, end uses, and region.s for the anti-tuberculosis therapeutics market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the anti-tuberculosis therapeutics market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q.1. What is the anti-tuberculosis therapeutics market size?
Answer: The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030.
Q.2. What is the growth forecast for anti-tuberculosis therapeutics market?
Answer: The global anti-tuberculosis therapeutics market is expected to grow with a CAGR of 7.1% from 2024 to 2030.
Q.3. What are the major drivers influencing the growth of the anti-tuberculosis therapeutics market?
Answer: The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.
Q.4. What are the major segments for anti-tuberculosis therapeutics market?
Answer: The future of the anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.
Q.5. Who are the key Anti-Tuberculosis Therapeutics Market companies?
Answer: Some of the key anti-tuberculosis therapeutics companies are as follows:
Q.6. Which anti-tuberculosis therapeutics market segment will be the largest in future?
Answer: Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.
Q.7. In anti-tuberculosis therapeutics market, which region is expected to be the largest in next 5 years?
Answer: APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.
Q.8. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.